SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?


To: Judy who wrote (16925)10/14/1998 5:14:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 120523
 
Judy, I agree with you absolutely. You're the expert in charting (I mean it!!!). I still own quite a bit of Pfizer in my long term holdings, so it doesn't matter that I missed out this morning's buying opportunity (would be a good trade, though). When you look at the fundamentals, it's a bit strange that analysts are so positive about Celebra's future contribution to PFE's bottomline, and yet Monanto (MTC) trades down so much.

Do you think that MTC's worth a look?



To: Judy who wrote (16925)10/19/1998 11:14:00 AM
From: Henry Niman  Respond to of 120523
 
The abstracts for next months Rheumatology meeting in San Diego are
available. Compare clinical data for MTC's Celebrex (Celebra) vs MRK's Vioxx in the Celebra Update section at biocognizance.com